Member Info for glasshalfdrunk

Not got any spare cash in my account to do a dummy buy! 😂

Dummy Sell £10,000 for 8.089

For entertainment, i just asked google what the chances of Mattpr ever being happy again?

I didnt know AI laughed. Harsh

Cheer up dude, you didnt used to be this bitter - better times are coming

Lufu, if the argon discovery is confirmed then there may be a very interested party in a neighbouring state - South Dakota.

The Deep Underground Neutrino Experiment (DUNE) collaboration is currently organizing delivery methods and schedules to identify and contract with liquid-argon vendors capable of supplying the required volumes. As of February 2026, the cryogenics team has awarded contracts for nitrogen systems and pumps, but contracts for the argon itself are expected to be placed in the coming year or two to align with the installation of the first detector module. The first two far detector modules alone will require approximately 1,000 truckloads (about 20,000 tons) of liquid argon, with the total experiment aiming for over 50,000 tons. (expected to be 70, 000 tons). Thats a lot of Argon!!

Courtesy of Claude...

Cost - Cost

This is where it gets complicated — no publicly disclosed per-tonne price has been published for the DUNE argon procurement contract. However, we can estimate:

Current bulk liquid argon market prices are in the range of $630–$720 per metric tonne in major markets as of early 2026. USGS

At 70,000 tonnes total, that implies a raw commodity cost of roughly $44–50 million just for the argon itself, before transport, liquefaction, underground delivery infrastructure, and purity processing.

The argon also needs to be of exceptional purity (parts-per-billion level for contaminants) which adds significant cost over standard industrial grade product.

The total cryogenics budget for LBNF/DUNE is far larger — the overall project cost is in the billions, with cryogenic systems being a major line item.

The argon is also not a one-time cost — it needs to be continuously recirculated and purified during operations, which means ongoing supply and filtration costs over the experiment's multi-decade lifetime.

In short: DUNE needs a staggering amount of argon, Air Products is the key infrastructure partner, and while the raw commodity cost alone runs to tens of millions of dollars, the total cryogenic system cost is a much larger number that Fermilab has not broken out publicly.

How valuable is undergorund Argon? - Claude says,

Extraordinarily valuable in specialist terms. A 70-day exposure of the Colorado UAr inside DarkSide-50 demonstrated that it contains a factor of greater than 1,400 times less Ar-39 compared to argon separated from the atmosphere. That 1,400x reduction in radioactive background is not something you can replicate with atmospheric argon at any price — it's a qualitative difference that simply opens up physics that is otherwise impossible.

For a DUNE-scale detector volume, UAr might be produced in an acceptable timescale of approximately five years at a roughly estimated cost of only three times that of atmospheric argon. "Only three times" is the scientists' way of saying it's more expensive but not prohibitively so at scale — though at 70,000 tonnes that still adds up to a meaningful premiu

Lordloadsoflolly - i think Skippy was just missing a comma which completely changes the meaning?!

'No video, and technical problems at the AGM - makes perfect sense

Global Policy Journal - By Omid Zamani and Mohammad Reza Farzanegan - 19 May 2026

Covers lots of the same ground as previous articles but make some goof suggestions that will only benefit producers such as Helix going forward.

'Omid Zamani and Mohammad Reza Farzanegan offer three policy steps to reduce vulnerabilities to Helium shortages.

The Strait of Hormuz is again at the centre of global policy debate. The current escalation around Iran and the Persian Gulf has revived familiar concerns about oil exports, liquefied natural gas, shipping insurance and energy prices. Recent commentary in Global Policy has described Hormuz as an economic weapon whose costs are transmitted through oil, gas, inflation and food-security channels. Our article extends this discussion to a less visible supply chain: helium.'

'This is a global policy issue because helium connects Gulf energy infrastructure to semiconductor supply chains. Our analysis of 2023 United Nations Comtrade data shows that several economies with large shares of global integrated-circuit exports also import substantial shares of their helium from the Persian Gulf . China, Singapore, Taiwan and Hong Kong are especially exposed, and together account for more than 60% of global integrated-circuit exports.'

'Governments have paid growing attention to critical minerals. They have mapped mining concentration, refining capacity, foreign direct investment, recycling potential and trade exposure. Helium needs a similar approach. Its risk profile is different, but its strategic importance is real. The issue is less about mine ownership and more about gas processing, liquefaction, storage, shipping corridors and industrial dependence.

Three policy steps would reduce this vulnerability.

First, major importing economies should map helium exposure. This means identifying source countries, shipping routes, liquefaction facilities, contract structures, inventories and critical end uses. Governments already do this for some strategic minerals. Helium should be included in these assessments.

Second, governments should create strategic helium reserves for priority uses. Healthcare, research infrastructure and semiconductor production should receive special attention. Reserve policy should include clear allocation rules, since conserving helium for essential uses is as important as storing it.

Third, governments should improve transparency in production, storage and trade flows. Helium markets remain relatively opaque. Better reporting would allow earlier warning of shortages, more credible risk assessment and better coordination among importing economies.

These measures would reduce, though not eliminate, geopolitical risk from the Persian Gulf. They would also reduce the capacity of a single maritime corridor to transmit shocks across distant production systems.

Extremely positive language

Anyone who subscribes - please feel free to expand!

Helix has agreed a short-term spot sales agreement for its helium production from Rudyard with a large industrial gases (IG) company. The high helium price, a major player's entry and their trailer capacity arrangement strongly affirm the Rudyard product's quality and Helix team's operational credibility. The company has not revealed the price for confidentiality reasons but stated that it significantly exceeded the company’s previously published price expectations of US$500/mcf .....

Enhertu’s market conquest is continuing apace. Already tracking at $5 billion in annual sales, the star antibody-drug conjugate from Daiichi Sankyo and AstraZeneca has secured the FDA’s approval to treat early breast cancer, further encroaching on the territory of Roche’s Kadcyla.

The FDA has simultaneously greenlighted Enhertu for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer, the two companies said Friday. The adjuvant nod came nearly two months ahead of schedule, as the FDA had originally targeted a decision by July 7.

While early, the adjuvant label comes with a catch: It precludes patients who’ve received Enhertu before surgery from continuing on the HER2-directed ADC in the post-operative setting.

Specifically, in the adjuvant setting, Enhertu is now approved for patients with HER2-positive breast cancer who have residual invasive disease following treatment with trastuzumab (Herceptin)—with or without Roche’s Perjeta—and taxane-based treatment. When announcing an FDA priority review in March, Daiichi and AZ described the indication as for “after neoadjuvant HER2 targeted treatment,” which, if approved verbatim, would cover prior use of Enhertu. But apparently a broad label did not pan out.

As for the neoadjuvant setting, Enhertu is cleared on top of the THP regimen (a taxane, Herceptin and Perjeta) for treating adults with HER2-positive stage 2 or stage 3 breast cancer.

Despite the label restriction, some doctors might still use Enhertu in the adjuvant setting following neoadjuvant Enhertu.

Enhertu’s adjuvant early breast cancer indication is backed by data from the Destiny-Breast05 trial showing the drug reduced the risk of invasive disease recurrence or death by 53% compared with Kadcyla.

In the neoadjuvant setting, the Destiny-Breast11 study linked Enhertu, followed by THP, to a pathologic complete response (pCR) rate of 67.3%, significantly higher than the 56.3% for dose-dense doxorubicin and cylophosphamid followed by THP. A pCR means no residual disease is found in resected tissues.

In interviews with Fierce at the European Society for Medical Oncology annul meeting in October, executives from Daiichi and AZ suggested that because neoadjuvant treatment only involves four cycles of Enhertu, doctors would not hesitate too much about retreating patients who have residual disease.

“If you’ve only had four cycles of Enhertu and you’ve had a really good response, I don’t think that that says that you’re going to necessarily be resistant to Enhertu for a re-challenge in that setting,” AZ’s oncology R&D chief Susan Galbraith, Ph.D., said at the time.

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate (ADC) that could have better luck binding to tricky target sites.

At the center of the deal is Parabilis’ Helicon peptide platform. Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets. Their superpower is an ability to attach to flat surfaces that would otherwise make traditional small molecule binding difficult.

Part of the collaboration with Regeneron will involve exploring the use of Helicons as standalone therapies. But Regeneron said it will have a “particular focus” on antibody-Helicon conjugates (AHCs).

These AHCs have a similar principle to ADCs—with an antibody helping to deliver a Helicon payload to the target site. Using a Helicon should mean these AHCs are able to selectively modulate intracellular proteins that are otherwise considered undruggable, Regeneron explained in a May 18 release.

New Helicons and AHCs discovered under the collaboration will be developed and commercialized by Regeneron.

The deal—which spans five initial targets—will see Parabilis receive $50 million in upfront cash as well as a $75 million equity investment from Regeneron. Down the line, Regeneron is liable to pay out up to $2.2 billion in milestones across those five targets, with the company having the option to select further targets if it fronts up more cash.

“This collaboration reflects Regeneron’s approach of advancing cutting-edge and diversified science to produce a robust portfolio of innovative medicines for patients in need,” Regeneron’s Chief Scientific Officer George Yancopoulos, M.D., Ph.D., said in a statement.

“In addition to the potential of Helicons to address previously undruggable targets, the collaboration’s intent to couple Helicons to our VelocImmune-derived antibodies so as to precisely deliver them to cells of interest represents an exciting new approach with the potential to create an entirely new therapeutic class that can span multiple therapeutic areas,” Yancopoulos said.

Parabilis CEO Mathai Mammen, M.D., Ph.D., said this morning that the biotech had already “demonstrated the potential of Helicon peptides to directly inhibit or degrade several disease-driving proteins in oncology that have long been considered out of reach.”

“We are thrilled to enter into a collaboration with Regeneron that builds on this foundation, combining the intracellular access and binding capabilities of our Helicons against challenging targets with antibodies from Regeneron,” Mammen added.

Sunda Energy Plc

("Sunda" or "Sunda Energy" or the "Company")

Conversion of Loan Notes and Issue of Warrants

Sunda Energy Plc (AIM: SNDA), the AIM-quoted oil & gas company focused on the Asia-Pacific region, announces that it has received notice from Alumni Capital (the "Investor"), who participated in the CLN Subscription as announced on 8 April 2026, to convert £250,000 of the outstanding balance of its Convertible Loan Notes plus a £25,000 Finance Charge (the "Conversion Balance") into ordinary shares of 0.1 pence each in the Company ("Ordinary Shares").

The conversion price of the Conversion Balance is 1.7827 pence (the "Conversion Price"), which, in accordance with the terms of the Convertible Loan Notes, is a 15% discount to the lowest daily volume weighted average price on any of the 10 Trading Days prior to the issue of the conversion notice (being 2.0973 pence).

Accordingly, the Company will issue 15,426,039 new Ordinary Shares (the "New Ordinary Shares") to the Investor (the "Conversion").

In addition, the Company has granted 8,899,676 CLN Warrants to the Investor pursuant to the Conversion. One CLN Warrant will entitle the Investor to subscribe for one Ordinary Share, at a 30% premium to the Conversion Price, being 2.3175 pence.

Details of the terms and conditions of the Convertible Loan Notes are outlined in the Company's announcement released on 8 April 2026 and in the Company's circular posted to shareholders on 9 April 2026.

Admission to AIM

Application will be made shortly to London Stock Exchange plc for the 15,426,039 New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on or around 21 May 2026.

Following Admission, the Company's issued share capital will comprise 400,941,457 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Nicely put, Mrs I 👍

By the end of 2021, the company's market cap was reported around $1.53 billion.The company was later acquired by Merck in 2023 for $200 per share

'When Prometheus Biosciences (RXDX) went public in March 2021, it priced its shares at $19.00 each. At this IPO price, the company had a market capitalization of approximately $657 million'

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a top five oncology player worldwide by 2035, plus a major 200 billion Japanese yen ($1.3 billion) cost optimization initiative.

By 2030, Daiichi envisions (PDF) its revenues will reach more than 3 trillion yen ($19.1 billion), with 2.3 trillion yen stemming from an oncology portfolio that it hopes to bulk up with more than 20 new indications across five medicines.

In fiscal year 2025, Daiichi achieved 2.1 trillion yen in total revenue—far exceeding an initial goal of 1.6 trillion set in 2021—with a 954-billion-yen ($6.1 billion) contribution from cancer drugs, driven mainly by two ADCs: AstraZeneca-partnered Enhertu and Datroway.

Over 240,000 patients have received treatment from the two ADCs. By 2035, Daiichi aims for its cancer drugs to reach more than 700,0000 new eligible patients annually.

Enhertu and Datroway will continue to be Daiichi’s main growth drivers in the next five years. But three more ADCs based on the company’s DXd platform are expected to reach the market during the period. These include Merck & Co.-partnered B7-H3-directed antibody-drug conjugate ifinatamab deruxtecan (I-DXd), awaiting an FDA decision in previously treated extensive-stage small cell lung cancer by Oct. 10, 2026.

The other two candidates are CDH6-directed raludotatug deruxtecan (R-DXd), which is under evaluation in ovarian cancer, and HER3-directed patritumab deruxtecan (HER3 DXd), which after a withdrawal of an FDA application in EGFR-mutate non-small cell lung cancer is now being tested in a phase 3 trial for HR-positive, HER2-negative breast cancer.

Daiichi is advancing other DXd ADCs, including DS-3939 targeting tumor-associated MUC1 and DS-3790 directed at CD37, both of which the company figures hold blockbuster potential.

Taken together, Daiichi expects its DXd technology alone will generate more than 3 trillion yen ($19.1 billion) in peak sales.

To drive future growth, Daiichi is developing new proprietary technologies that have the potential to match the impact of DXd, some even beyond oncology.

On the ADC side, Daiichi is devising next-generation cytotoxic payloads to overcome resistance to DXd, and additional efforts to design novel tumor-selective antibodies are underway, with plans to enter human studies in fiscal 2027.

Another type of payload that Daiichi is working on tries to activate the immune system via the STING pathway and achieve long-term immune memory. A phase 1 study for such a candidate, called DS3610, is ongoing.

Looking beyond ADCs, Daiichi is eyeing platforms for multi-specific antibodies, target protein degraders and small interfering RNA. Those technologies are either already in clinical testing or slated to begin phase 1 study this year, according to Daiichi.

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion Japanese yen ($610 million) hit linked to its precautionary antibody-drug conjugate (ADC) manufacturing strategy.

To hear Daiichi tell it, the downward revision reflects the cost of its own precautionary planning; by aggressively earmarking capacity to ensure a stable supply, Daiichi left itself vulnerable to the shifting demand of its ADC portfolio.

Daiichi earned its first ADC approval from the FDA—for AstraZeneca-partnered Enhertu—at the end of 2019. As the portfolio grew, estimated demand expanded significantly beyond expectations. Therefore, Daiichi “adopted a policy of securing manufacturing capacity sufficient to cover maximum demand without risk adjustment, with the highest priority placed on ‘ensuring a stable supply to all patients,’” the company explained in a May 8 release.

As a result, Daiichi signed long-term contracts with CMOs, committing to minimum purchases while securing dedicated production lines. The company was apparently trying to avoid potential shortages given the small number of CMOs with ADC capabilities and the infancy of its own manufacturing capacity.

However, clinical trial results led to revisions to target patient populations, while delays in launch timelines further reduced Daiichi’s forecast for demand.

TROP2-directed Datroway, Daiichi’s second ADC from its AZ collaboration to reach the market, showed limited efficacy in second-line non-small cell lung cancer, leading to a revised FDA application and eventual go-ahead in an EGFR-mutated niche last summer.

Daiichi has updated its ADC supply plan, incorporating risk adjustment. The compensation of 75.7 billion yen to contractors reflects short-term differences from the old strategy. As for the mid- to long-term gaps, Daiichi has not made any adjustments yet “due to the high level of uncertainty,” the company said.

Alde

You say 'All these folks want to do is log in here listen to JHFH warm fuzzy words despite him being constantly wrong and then log out again' Thats because this is a HEMO board to talk about Hemo things, Avacta has its own board to talk about Avacta things - its that simple.

Hemo v Avacta is not a competition - they dont do the same things, lets hope they both succeed and go a long way to improving cancer patients lives and make their shareholders (who have the bottle to hold, not trade) wealthy in the process

Cheers Kaeren, i particularly liked the reply to the post...

'Here is what the chart doesn't show:

the 17% semiconductor share of global helium consumption is the most supply-inelastic segment in the entire pie. Chip fabs cannot reduce helium consumption without stopping production. There is no substitution. There is no workaround. When helium is unavailable, lithography stops.

The US at 42.6% looks reassuring until you understand the distribution problem. US helium production is concentrated in a handful of fields in Wyoming, Kansas and the Texas Panhandle. The infrastructure to liquefy, transport and deliver it to semiconductor fabs in Taiwan, South Korea and Japan is entirely dependent on cryogenic tanker shipping, the same routes disrupted by the Hormuz situation.

Russia at 9.5% is effectively inaccessible for Western buyers under current sanctions. That removes another alternative.

The practical picture for semiconductor procurement: effective available supply well below the headline production numbers suggest.'

'....after Kresladi gene therapy approval.Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 million sale that reflects the high market demand for a speedy FDA review.

Rocket earned its voucher from its late March accelerated approval of hematopoietic stem cell-based gene therapy Kresladi, which was cleared to treat certain children with severe leukocyte adhesion deficiency-1 (LAD-1).

With the sale, which transferred the PRV to an unknown buyer, the company extends its cash runway into the second quarter of 2028, CEO Gaurav Shah, M.D., noted in a Tuesday press release. Rocket specifically plans to use the proceeds to support the advancement of its cardiovascular gene therapy pipeline. PRVs are given alongside certain FDA approvals, including for rare pediatric disease drugs. While PRV awardees can use the voucher themselves to fast-track another drug application from the standard 10-month review period to six months, they are sometimes sold to other companies, given the immediate monetary return, which can be crucial for smaller biotechs.'

C'mon Vlad lets get cracking with the paediatric expansion

For those not on Linked In - Cellin just posted the following " Cellin Technologies has received a 5-year extension of its Hospital Exemption authorization from the Estonian State Agency of Medicines (Ravimiamet) for AngioARC. This extension reflects continued regulatory confidence in our approach and the growing clinical experience accumulated within a highly controlled framework. We are also proud to announce that we have now treated our 13th patient with AngioARC, further contributing to real-world evidence in patients with critical limb-threatening ischemia, where therapeutic options remain extremely limited. We remain committed to advancing AngioARC with scientific rigour and clinical responsibility, with the goal of improving outcomes for patients facing the risk of major limb loss. We sincerely thank our clinical partners, team, and the Estonian regulatory authorities for their continued trust and collaboration."

Fairly Broad brush article in Times Business section today - doesn't tell us anything that we don't already know but still nice to see it written in Black and white in a Broadsheet

Titled - Winners and losers across the global economy' as Iran war drags on From windfalls for oil majors and financial markets, to stranded shipping, disrupted supply chains and the risk of food shortages, what does the future hold?

With the war about to enter its ninth week, we look at the impact on key sectors.

It covers Energy, Shipping, Finance, retail, Agriculture, Travel, Defence and Technology.

The Helium shortage/pricing was the focus under Technology -

' One of the less well-known components of the advanced manufacturing and artificial intelligence supply chain is helium.

The gas is used across multiple stages of semiconductor manufacturing, including temperature control and maintaining the ultra-clean and stable conditions required for producing chips.

The war in Iran has severely disrupted the global supply of helium. Roughly one third of the world’s supply passes through the Strait of Hormuz, primarily originating from Qatar where it is developed as a by-product of LNG manufacturing. Since the start of the war, spot helium prices have doubled. '